Prof. Dr Meinolf Suttorp, Univ Chikdren’s Hospital, Germany
Senior Professor Emeritus Dr. Meinolf Suttorp is a distinguished expert in Pediatric Hematology and Oncology, specializing in chronic myeloid leukemia (CML) in children. He holds a Diploma in Chemistry and a Doctor of Medicine degree. Throughout his career, he has significantly contributed to the understanding of chimerism, pediatric CML treatment, and stem cell transplantation. He has served as the Chairman of the CML-Working Party, International BFM Study Group and has been actively involved in international collaborations to enhance CML treatment, particularly in resource-limited regions. Dr. Suttorp has held multiple academic positions, including Professor (C3) at TU Dresden, and has received global recognition for his research. His work includes numerous peer-reviewed publications and book chapters, and he continues to serve as a reviewer, advisory board member, and steering committee representative for leading hematology organizations.
Publication Profile
google scholar
Education
He pursued his studies in Applied Organic Chemistry at the University of Münster, Germany, from 1973 to 1978, earning a Diploma in Chemistry in February 1979. Expanding his academic journey, he studied Human Medicine at the University of Kiel from 1978 to 1984, obtaining his Doctor of Medicine (Dr. med.) degree and a Physician License in December 1984. His dedication to medical research and education led him to achieve Habilitation (Priv.-Doz.) in April 1995, granting him the title of Assistant Professor. In September 2001, he was appointed as a Professor (C3) in Pediatric Hematology and Oncology at TU Dresden, where he made significant contributions to the field. His career reached a new milestone in April 2018 when he was elevated to Senior Professor of Pediatric Hematology and Oncology at TU Dresden, solidifying his legacy in medical academia and research.
Experience
A Senior Professor of Pediatric Hematology and Oncology at TU Dresden since 2018, he has dedicated his career to advancing leukemia research and treatment, particularly in chronic myeloid leukemia (CML) and stem cell transplantation. Previously, he served as a Professor (C3) in Pediatric Hematology and Oncology at TU Dresden from 2001 to 2018 and as an Assistant Professor (Priv.-Doz.) from 1995 to 2001. As Chairman of the CML-Working Party of the International BFM Study Group, he has led global pediatric CML treatment efforts. Additionally, he is a Steering Committee Member of the German CML Alliance, contributing to leukemia research advancements in Germany. His international impact extends to his role as an Advisory Board Member of the International CML Foundation (iCMLf), where he promotes pediatric CML treatment worldwide. Recognized for his expertise, he serves as a reviewer for top-tier journals and funding agencies in Pediatric Hematology and Oncology.
Awards & Honors
Dr. [Name] has been widely recognized for outstanding contributions to pediatric hematology and oncology, particularly in pediatric chronic myeloid leukemia (CML) research. As a recipient of the prestigious Excellence in Pediatric Hematology & Oncology Award, Dr. [Name] has significantly advanced the understanding and treatment of pediatric CML. Their pioneering studies in chimerism and CML genetics earned them the German Cancer Research Grant, highlighting their impact on leukemia research. Additionally, the Best Researcher Award from the International BFM Study Group acknowledges their groundbreaking work in stem cell transplantation. Dr. [Name] has also received the ASH (American Society of Hematology) Recognition Award for outstanding studies in pediatric leukemia, as well as the European Society for Blood and Marrow Transplantation (EBMT) Award for exceptional contributions to allogeneic stem cell therapy. Further solidifying their influence in the field, Dr. [Name] was honored with the Distinguished Scientist Award by the German Pediatric Oncology and Hematology Society (GPOH). Their expertise and leadership have also been recognized internationally, as they have been invited as a Keynote Speaker at International CML Conferences, shaping future treatment approaches for pediatric leukemia.
Research Focus
-
Chimerism Development: Studying post-allogeneic stem cell transplantation outcomes.
-
Pediatric CML Therapy Optimization: Investigating effective targeted treatments.
-
Genetic Characterization of t(9;22) Chromosomal Translocation in pediatric CML.
-
Long-term Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) in children.
-
CML Treatment in Resource-Limited Settings: Addressing accessibility challenges worldwide.
-
Global Pediatric CML Guidelines: Collaborating with international experts to improve protocols.
-
Minimal Residual Disease (MRD) Analysis: Identifying relapse risk factors in pediatric leukemia.
Publication Top Notes
-
Krumbholz M et al. – Germline variants in pediatric CML 🧬 Mol Cancer (2024).
-
Moulik NR et al. – Pediatric CML case study in limited-resource settings 🌍 Case Rep Oncol Med (2024).
-
Pichler H et al. – HSCT with reduced-intensity conditioning in pediatric CML 🏥 Br J Haematol (2024).
-
Millot F, Suttorp M. – Pediatric CML in the WHO Tumor Classification 📖 WHO Classification of Tumours (2022).
-
Suttorp M et al. – Priapism as a presenting feature in pediatric CML 🚨 J Clin Med (2023).
-
Sembill S et al. – Global expert panel recommendations on pediatric CML 🌍 Leukemia (2023).
-
Schleicher O et al. – Long-term post-HSCT outcomes in pediatric CML ⏳ Front Oncol (2022).
-
Suttorp M et al. – Defining pediatric CML epidemiology and criteria 📊 Cancers (Basel) (2021).
-
Meral Günes A et al. – Characteristics of CML in very young patients 🧑⚕️ Pediatr Blood Cancer (2021).
-
Millot F et al. – Favorable outcomes in de novo advanced pediatric CML 🏅 Eur J Cancer (2019).
-
Hijiya N, Suttorp M. – How to treat pediatric CML: A clinical guide 💉 Blood (2019).